Bart Neyns
Expertise in
8
conditions

Bart Neyns

Universitair Ziekenhuis Brussel
Brussels, BRU, BE 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
8
conditions
Universitair Ziekenhuis Brussel
Brussels, BRU, BE 

Overview

Bart Neyns practices practicing medicine in Brussels, Belgium.

Mr. Neyns is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Melanoma, Glioblastoma, Astrocytoma, Glioma, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 190 peer reviewed articles and participating in 8 clinical trials.

Gender

Male

Locations

Universitair Ziekenhuis Brussel
Brussels, BRU, Belgium
Other Locations
CHU Liège
Liege, WAL, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: June 24, 2026
Intervention Type: Genetic
A Randomized Phase II Clinical Trial on Intratumoral AS01B/ipilimumab Plus Intravenous Nivolumab with or Without Autologous CD1c(BDCA-1)+ / CD141(BDCA-3)+ Myeloid Dendritic Cells.
A Randomized Phase II Clinical Trial on Intratumoral AS01B/ipilimumab Plus Intravenous Nivolumab with or Without Autologous CD1c(BDCA-1)+ / CD141(BDCA-3)+ Myeloid Dendritic Cells.
Enrollment Status: Recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma
A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: November 21, 2025
Intervention Type: Drug, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes
Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes
Enrollment Status: Unknown
Publish Date: August 19, 2024
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
TraMel-WT: A Stratified Dual-stratum Open-label Two-stage Phase 2 Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma
TraMel-WT: A Stratified Dual-stratum Open-label Two-stage Phase 2 Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma
Enrollment Status: Completed
Publish Date: September 26, 2023
Intervention Type: Drug
Study Drugs: Trametinib, Dabrafenib
Study Phase: Phase 2
A Phase IB Clinical Trial on Adjuvant Low-dose Ipilimumab Plus Nivolumab Following the Resection of Melanoma Macrometastases
A Phase IB Clinical Trial on Adjuvant Low-dose Ipilimumab Plus Nivolumab Following the Resection of Melanoma Macrometastases
Enrollment Status: Completed
Publish Date: January 24, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase II Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
Phase II Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: January 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Clinical Trial on Decitabine (5-aza-2'-Deoxycytidine) Administered by Hepatic Arterial Infusion in Patients With Unresectable Liver-predominant Metastases From Colorectal Cancer
A Phase I Clinical Trial on Decitabine (5-aza-2'-Deoxycytidine) Administered by Hepatic Arterial Infusion in Patients With Unresectable Liver-predominant Metastases From Colorectal Cancer
Enrollment Status: Completed
Publish Date: October 27, 2017
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

190 Total Publications

The past, present, and future treatment of BRAFV600-mutant metastatic colorectal cancer: A comprehensive review.
The past, present, and future treatment of BRAFV600-mutant metastatic colorectal cancer: A comprehensive review.
Journal: Cancer
Published: May 06, 2026

Frequently Asked Questions about Bart Neyns

Is Bart Neyns a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Bart Neyns is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Bart Neyns participate in research or clinical trials?

Yes. Bart Neyns has published 190 articles and abstracts on conditions like Melanoma. You can view a list of Bart Neyns's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Neyns's expertise for a condition
ConditionClose
View All 18 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile